{"id":170207,"date":"2025-08-15T04:08:31","date_gmt":"2025-08-15T08:08:31","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170207"},"modified":"2025-08-15T04:08:31","modified_gmt":"2025-08-15T08:08:31","slug":"astrazeneca-pharma-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/astrazeneca-pharma-q1-fy26-earnings-results\/","title":{"rendered":"Astrazeneca Pharma Q1 FY26 Earnings Results"},"content":{"rendered":"<p>AstraZeneca Pharma India Limited is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Below are its <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/48cf5f79-c911-46e4-9d72-4828940b3d02.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> Earnings Results.<\/p>\n<h2><strong>Q1 FY26 Earnings Results<\/strong><\/h2>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b9826 crore, up 29.06% year-on-year (YoY) from \u20b9640 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b9726 crore, up 20.40% YoY from \u20b9603 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b997 crore, up 130.95% from \u20b942 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b90.61, up 771.43% from \u20b90.07 YoY.<\/li>\n<\/ul>\n<h2><strong>Operational &amp; Strategic Update<\/strong><\/h2>\n<ul>\n<li><strong>Robust Top-line Growth:<\/strong> Revenues rose by 29% YoY, reflecting increased demand, new product launches, and improved market reach.<\/li>\n<li><strong>Cost Control:<\/strong> Expenses increased at a slower pace than revenues, indicating effective cost management and operational efficiencies.<\/li>\n<li><strong><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/48cf5f79-c911-46e4-9d72-4828940b3d02.pdf\" target=\"_blank\" rel=\"noopener\">Exceptional Profit Expansion<\/a><\/strong><strong>:<\/strong> Net profit grew by nearly 131%, benefiting from higher sales, improved gross margins, and leveraged cost structures.<\/li>\n<li><strong>Market Strength &amp; Innovation:<\/strong> AstraZeneca Pharma India continues to focus on strengthening its medicine portfolio, expanding its therapeutic footprint, and leveraging research-driven innovation for growth.<\/li>\n<li><strong>Distribution &amp; Reach:<\/strong> The company\u2019s efficient pan-India distribution and marketing networks support its ability to capture emerging market opportunities.<\/li>\n<\/ul>\n<h2><strong>Corporate Developments in Q1 FY26 Earnings<\/strong><\/h2>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/48cf5f79-c911-46e4-9d72-4828940b3d02.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> results showcase AstraZeneca Pharma India\u2019s ability to capitalize on product demand, drive margin expansion, and achieve rapid earnings growth through a combination of commercial execution and operational discipline.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-170208\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png\" alt=\"ASTRAZEN Q1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<h2><strong>Looking Ahead<\/strong><\/h2>\n<p>AstraZeneca Pharma India Ltd intends to expand its product offerings, invest in innovative therapies, and strengthen its footprint in key therapeutic areas. Enhanced manufacturing efficiencies and continued focus on market expansion are expected to support sustained profitability and value creation through FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts,<a href=\"https:\/\/44.250.171.167\/symbol\/astrazen\/\"> click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca Pharma India Limited is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9826 crore, up 29.06% year-on-year (YoY) from \u20b9640 crore in Q1 FY25. Total Expenses: \u20b9726 crore, up 20.40% YoY from \u20b9603 crore. Consolidated Net Profit (PAT): \u20b997 crore, [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":170208,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-170207","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ASTRA.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170447,"url":"https:\/\/alphastreet.com\/india\/aarti-drugs-q1-fy26-earnings-results\/","url_meta":{"origin":170207,"position":0},"title":"Aarti Drugs Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 21, 2025","format":false,"excerpt":"Aarti Drugs Ltd, established in 1984 and part of the $1000 million Aarti Group of Industries, is engaged in manufacturing and selling Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals, as well as pharmaceutical formulations. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b9591 crore,\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AARTIDRUGS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AARTOI.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170582,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":170207,"position":1},"title":"Alkem Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25. Total Expenses: \u20b92,750 crore, up 8.61%\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALKEM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172230,"url":"https:\/\/alphastreet.com\/india\/mankind-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":170207,"position":2},"title":"Mankind Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 7, 2025","format":false,"excerpt":"Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products. \u00a0 Q2 FY26 Earnings Results Revenue from Operations: \u20b93,697.16 crore, up 20.77% YoY and 3.55% QoQ. EBITDA: \u20b9924 crore, with an EBITDA margin of 25.0%, representing\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Mankind Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Mankind-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169833,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-ltd-q1-fy26-earnings-results-revenue-up-4-net-profit-falls-10-yoy\/","url_meta":{"origin":170207,"position":3},"title":"Aurobindo Pharma Ltd Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 6, 2025","format":false,"excerpt":"Aurobindo Pharma Limited is a key player in the pharmaceutical industry. It manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company supports global healthcare with a broad product portfolio that serves both developed and emerging markets. Financial Highlights In Q1 FY26, Aurobindo Pharma reported revenue\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AU.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170544,"url":"https:\/\/alphastreet.com\/india\/akums-q1-fy26-earnings-results\/","url_meta":{"origin":170207,"position":4},"title":"Akums Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Akums Drugs & Pharmaceuticals Ltd, established in 2004, is a pharmaceutical contract development and manufacturing organization (CDMO) offering a wide range of pharmaceutical products and services. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b91,024 crore, up 0.49% year-on-year (YoY) from \u20b91,019 crore in Q1 FY25.\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"AKUMS Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/AKUMS.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169565,"url":"https:\/\/alphastreet.com\/india\/ajanta-pharma-ltd-q1-fy26-earnings-results-revenue-up-13-8-net-profit-up-3-7-yoy\/","url_meta":{"origin":170207,"position":5},"title":"Ajanta Pharma Ltd Q1 FY26 Earnings Results \u2013 Revenue Up 13.8%, Net Profit Up 3.7% YoY","author":"Divyansh_Kasana","date":"July 30, 2025","format":false,"excerpt":"Ajanta Pharma Limited is a specialty pharmaceutical company primarily engaged in the development, manufacturing, and marketing of high-quality finished dosage formulations. The company focuses on delivering innovative and affordable medicines across multiple therapeutic segments, strengthening its presence in domestic and international markets. Q1 FY26 Earnings Summary (Apr\u2013Jun 2025) Revenue: \u20b91,303\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/AJANTA.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170207"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170207\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170208"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}